Coverage: The Meridian legal market record (editorial).
An expansion of an existing voluntary licence held by an Egyptian manufacturer, covering 120 high-incidence countries most of which are in Africa.
| Record ID | TX-AFR-2026-0070 |
|---|---|
| Record type | Commercial IP transaction |
| Transaction type | Licence extension, Non-exclusive licence |
| IP rights | patent, regulatory data, know-how |
| Status | Amended |
| Qualifying date | 2026-09-16 |
| Sector | Life sciences · HIV prevention (antiretrovirals) |
| African markets | Egypt, South Africa |
| Licensed territory | 120 high-incidence, resource-limited countries (primarily low- and lower-middle-income). |
| Disclosed value | Not disclosed in the sources reviewed. |
| Evidence | Primary source, independently corroborated · 2 source(s) |
| Last verified | 2026-10-25 |
Parties
- Gilead Sciences, Inc. (United States): licensor
- Eva Pharma for Pharmaceutical Industries S.A.E. (Egypt): licensee, manufacturer
- Dr. Reddy's Laboratories Limited (India): licensee
- Hetero (India): licensee
Key terms
- Interest: non-exclusive royalty-free voluntary licence (scope expanded); Exclusivity: non-exclusive; Territorial scope: 120 high-incidence countries; Term: Royalty-free; term not stated
- Financial terms as reported: “six royalty-free voluntary licensing agreements”
Sources
- Gilead accelerates global access planning for investigational once-yearly lenacapavir for HIV prevention, Gilead Sciences, 2026-09-16
- Gilead extends lenacapavir licensing deals to cover investigational once yearly HIV prevention shot, Biopharma Asia, 2026-10-20
Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.


